Literature DB >> 18406652

Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication.

Tohti Amet1, Mizuho Nonaka, Md Zahidunnabi Dewan, Yasunori Saitoh, Xiaohua Qi, Shizuko Ichinose, Naoki Yamamoto, Shoji Yamaoka.   

Abstract

Latent infection of human immunodeficiency virus type 1 (HIV-1) represents a major hurdle in the treatment of acquired immunodeficiency syndrome (AIDS) patients. Statins were recently reported to suppress acute HIV-1 infection and reduce infectious virion production, but the precise mechanism of inhibition has remained elusive. Here we demonstrate that lypophilic statins suppress HIV-1 virion release from tumor necrosis factor alpha-stimulated latently infected U1 cells through inhibition of protein geranylgeranylation, but not by cholesterol depletion. Indeed, this suppression was reversed by the addition of geranylgeranylpyrophosphate, and a geranylgeranyltransferase-1 inhibitor reduced HIV-1 production. Notably, silencing of the endogenous Rab11a GTPase expression in U1 cells by RNA interference destabilized Gag and reduced virion production both in vitro and in NOD/SCID/gammac null mice. Our findings thus suggest that small GTPase proteins play an important role in HIV-1 replication, and therefore could be attractive molecular targets for anti-HIV-1 therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18406652     DOI: 10.1016/j.micinf.2008.01.009

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  23 in total

1.  Identification of cellular proteins required for replication of human immunodeficiency virus type 1.

Authors:  Natallia Dziuba; Monique R Ferguson; William A O'Brien; Anthony Sanchez; Andrew J Prussia; Natalie J McDonald; Brian M Friedrich; Guangyu Li; Michael W Shaw; Jinsong Sheng; Thomas W Hodge; Donald H Rubin; James L Murray
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-20       Impact factor: 2.205

2.  Type I Interferon Counteracts Antiviral Effects of Statins in the Context of Gammaherpesvirus Infection.

Authors:  Philip T Lange; Eric J Darrah; Emily P Vonderhaar; Wadzanai P Mboko; Michaela M Rekow; Shailendra B Patel; Duska J Sidjanin; Vera L Tarakanova
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

3.  Statins as anti-inflammatory therapy in HIV disease?

Authors:  Andrew Carr
Journal:  J Infect Dis       Date:  2011-01-25       Impact factor: 5.226

4.  Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies.

Authors:  Hong Jiang; Xiaoyu Zhang; Xiao Chen; Pornpun Aramsangtienchai; Zhen Tong; Hening Lin
Journal:  Chem Rev       Date:  2018-01-02       Impact factor: 60.622

5.  Antileishmanial effect of mevastatin is due to interference with sterol metabolism.

Authors:  Neeradi Dinesh; Neelagiri Soumya; Sushma Singh
Journal:  Parasitol Res       Date:  2015-07-18       Impact factor: 2.289

Review 6.  The role of statins in the setting of HIV infection.

Authors:  Allison Ross Eckard; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

7.  U1 and OM10.1. Myeloid Cell Lines as Surrogate Models of Reversible Proviral Latency.

Authors:  Guido Poli
Journal:  Methods Mol Biol       Date:  2022

Review 8.  Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Luis Barcena; Randall Tressler
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

9.  Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice.

Authors:  Yohichi Kumaki; John D Morrey; Dale L Barnard
Journal:  Future Virol       Date:  2012-08       Impact factor: 1.831

10.  Low-Density Lipoprotein Receptor Suppresses the Endogenous Cholesterol Synthesis Pathway To Oppose Gammaherpesvirus Replication in Primary Macrophages.

Authors:  C A Aurubin; D A Knaack; D Sahoo; V L Tarakanova
Journal:  J Virol       Date:  2021-08-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.